#### **DEPARTMENT OF HEALTH**

NO. 2685 28 October 2022

# MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT No. 101 OF 1965) SCHEDULES

The Minister of Health has, in terms of section 22A (2) of the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), on the recommendation of the South African Health Products Regulatory Authority (SAHPRA), made and updated the Schedules.

This Schedule amends the Schedules as inserted by Government Notice R.509 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 24727, 10 April 2003; substituted by Government Notice R.935 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 31387, 5 September 2008; and amended by Government Notice R.1230 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 32838, 31 December 2009; Government Notice R.227 (Medicines and Related Substances Act: Schedules)in Government Gazette 35149, 15 March 2012; Government Notice R.674 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 36827, 13 September 2013, Government Notice R.690 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 36850, 20 September 2013, Government Notice R.104 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 37318, 11 February 2014; Government Notice R.352 (Medicines and Related Substances Act, 1965: Schedules) in, Government Gazette 37622, 8 May 2014; Government Notice R.234 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 38586, 20 March 2015; Government Notice R.254 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 39815, 15 March 2016; Government Notice R.254 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 40041, 03 June 2016; Government Notice No.748 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 41009, 28 July 2017; Government Notice No.1261 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 41256, 17 November 2017; Government Notice No.1262 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette

42052, 23 November 2018 and Government Notice No.755 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 42477, 23 May 2019; Government Notice No. R219 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 430151, 28 February 2020, Government Notice No. R586 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 43347, 22 May 2020, Government Notice No. R1375 (Medicines and Related Substances Act1 1965: Schedules) in Government Notice No. 883 (Medicines and Related Substances Act1 1965: Schedules) in Government Gazette 45176, 17 September 2021 using the following convention:

- Words in bold and in square brackets (e.g. [Gamma benzene hexachloride] in Schedule 1), indicate omission from a Schedule
- Words underlined with a solid line (e.g. <u>Gamma benzene hexachloride</u>), indicate insertions in a Schedule.

## **SCHEDULE**

In these Schedules, "the Act" means the Medicines and Related Substances Act, 1965 (Act No.101 of 1965)

Note: Where an alternative schedule(s) is included in natural parentheses at any point of an inscription, this is provided to indicate one or more alternative scheduling designation/s. This is for information only and shall not be used in the interpretation of such inscription.

#### **SCHEDULE 1**

- a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for
  - industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and
  - (ii) analytical laboratory purposes.
- b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:

- (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and
- (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.
- c. In terms of section 22A(4)(a)(v) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act No. 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 1 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act.

(i) Annexure 1A:

Emergency Care Provider (Paramedic);

Annexure 1B:

Emergency Care Provider (Emergency Care

Practitioner):

Annexure 1C:

Basic Ambulance Assistant

Annexure 1D:

Ambulance Emergency Assistant

Annexure 1E:

Emergency Care Technician

Annexure 1F:

**Emergency Care Assistant** 

(ii) Annexure 2:

Dental Therapist;

(iii) Annexure 3:

Optometrist.

(iv) Annexure 4:

Podiatrist

(v) Annexure 5:

Oral hygienists

#### <u>Dequalinium</u>

- (a) when intended for oral topical use, as oral solutions or lozenges;
- (b) except when intended for human vaginal use (S2)

#### **Phenylephrine**

- a. when intended for oral dosage forms, nasal dosage forms, or ophthalmic dosage forms containing more than 0,2 percent (S1)
- b. <u>except ophthalmic preparations containing 0,2 percent or less.</u> (S0)
- c. <u>except when intended for injection (S4)</u>

# **ANNEXURE 5: ORAL HYGIENISTS**

**Oral hygienists** registered with the Health Professions Council of South Africa (HPCSA) in terms of the Health Professions Act, 1974 (Act 56 of 1974)

ORAL HYGIENISTS	
LOCAL ANAESTHETIC	
Substance	: Lignocaine/Lidocaine hydrochloride
Indication	: Dental surface anaesthesia (excluding injectables)
Route of Administration	: Topical
TOPICAL FLUORIDES	
Substance	: -
Indication	: Applicable to dentistry
Route of administration	: Topical

- END SCHEDULE 1 -

## **SCHEDULE 2**

- a. All substances referred to in this Schedule are excluded when specifically packed, labeled, sold and used for
  - (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and
  - (ii) analytical laboratory purposes.
- All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:
  - (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and
  - (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.
- c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within their scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 2 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act.

(i) Annexure 1A: Emergency Care Provider (Paramedic);

Annexure 1B: Emergency Care Provider (Emergency Care

Practitioner);

Annexure 1C: Basic Ambulance Assistant

Annexure 1D: Ambulance Emergency Assistant

Annexure 1E: Emergency Care Technician

Annexure 1F: Emergency Care Assistant

(ii) Annexure 2: Dental Therapist;

(iii) Annexure 3: Optometrist.

(iv) Annexure 4: Podiatrist

## **Dequalinium**

- (a) when intended for human vaginal use;
- (b) except when intended for oral topical use, as oral solutions or lozenges (S1)

#### Estriol,

- a. When intended for human vaginal use
- b. except when intended for oral contraception; (S3)
- c. except when intended for hormone replacement therapy. (S4)
- d. except when intended for veterinary use (S4)

Rizatriptan, when in oral solid dosage forms providing 5 mg or less and presented as packs of no more than 2 oral solid dosage forms, indicated for the acute relief of migraine attacks, with or without aura, in patients previously diagnosed by a medical practitioner and initiated on treatment with rizatriptan (S4)

## **ANNEXURE 4: PODIATRIST**

PODIATRIST registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974)

## **PODIATRIST**

Anti-inflammatories

Substance

: Diclofenac sodium and Ibuprofen

Indication

: Pain management

Route of Administration : Oral

# - END SCHEDULE 2 -

## SCHEDULE 3

- All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for -
  - (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and
  - (ii) analytical laboratory purposes.
- b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:
  - The salts and esters of such substances, where the existence of such salts and esters is possible; and
  - (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 3 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act.

(i) Annexure 1A: Emergency Care Provider (Paramedic);

(ii) Annexure 1B: Emergency Care Provider (Emergency Care Practitioner);

(iii) Annexure 2: Dental Therapist;

(iv) Annexure 3: Optometrist.

(v) Annexure 4: Podiatrist

#### Estriol,

- a. when intended for oral contraception
- b. except when intended for human vaginal use (S2);
- c. except when intended for hormone replacement therapy. (S4)
- d. except when intended for veterinary use (S4)

## Folinic acid (leucovorin)

## Levalbuterol

- END SCHEDULE 3 -

## **SCHEDULE 4**

- a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for
  - industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and
  - (ii) analytical laboratory purposes.
- All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:
  - (ii) The salts and esters of such substances, where the existence of such salts and esters is possible; and

- (iii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.
- c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 4 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act.

(i) Annexure 1A: Emergency Care Provider (Paramedic);

Annexure 1B: Emergency Care Provider (Emergency Care Practitioner);

Annexure 1C: Basic Ambulance Assistant

Annexure 1D: Ambulance Emergency Assistant

Annexure 1E: Emergency Care Technician

Annexure 1F: Emergency Care Assistant

(ii) Annexure 2: Dental Therapist;

(iii) Annexure 3: Optometrist.

(iv) Annexure 4: Podiatrist

<u>Alectinib</u>

Alpelisib

<u>Apalutamide</u>

Asciminib

**Bedinvetmab** 

**Bictegravir** 

Cabotegravir

Cabozantinib

Casirivimab

Dacomitinib

Dapivirine

**Darolutamide** 

# [Dequalinium]

# **Entrectinib**

# Estriol,

- a. when intended for hormone replacement therapy
- b. when intended for veterinary use
- c. except when intended for oral contraception; (S3)
- d. except when intended for human vaginal use (S2);

## <u>Faricimab</u>

<u>Fremanezumab</u>

Glucagon

<u>Guselkumab</u>

<u>lcatibant</u>

<u>Idebenone</u>

<u>Imdevimab</u>

<u>Inclisiran</u>

<u>Itopride</u>

<u>Letermovir</u>

Linagliptin

**Molnupiravir** 

<u>Neratinib</u>

Noradrenaline (norepinephrine)

## Oloparib

## **Phenylephrine**

- a. when intended for injection
- b. <u>except ophthalmic preparations containing 0,2 percent or less. (S0)</u>
- c. <u>except for oral dosage forms, nasal dosage forms, or ophthalmic dosage forms</u>
  <u>containing more than 0,2 percent (S1)</u>

<u>Polatuzumab</u>

**Pralsetinib** 

Pretomanid

Recombinant human epidermal growth factor (rhEGF)

Remdesivir

Revefanacin

Risdiplam

Rizatriptan, except when in oral solid dosage forms providing 5 mg or less and presented as packs of no more than 2 oral solid dosage forms, indicated for the acute relief of migraine attacks, with or without aura, in patients previously diagnosed by a medical practitioner and initiated on treatment with rizatriptan (S2)

<u>Safinamide</u>

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine

<u>Satralizumab</u>

Selexipag

**Tafamidis** 

<u>Tivozanib</u>

**Tozinameran** 

Turoctocog Alpha

<u>Upadacitinib</u>

Zofenopril

# **ANNEXURE 3: OPTOMETRISTS**

**OPTOMETRIST** (Bachelors degree in Optometry – B OPTOM) registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974) and recognised by the Health Professions Council of South Africa as an authorised prescriber.

## **OPTOMETRISTS**

**ANTIBIOTICS** 

Substance

Fuscidic acid

Indication

For Blepharitis and stye

Route of Administration

Topical drops or ointment

**OPTOMETRISTS** 

**ANTIBIOTICS** 

Substance : Neomycin

Indication : For Blepharitis only

Route of Administration : Topical drops or ointment

**ANTIBIOTICS** 

Substance : Bacitracin

Indication : For Blepharitis only

Route of Administration : Ointment

**ANTIBIOTICS** 

Substance : Polymyxin B

Indication : For Blepharitis only

Route of Administration : Ointment PROSTAGLANDIN ANALOGUES (PGAs)

Substance : Latanoprost, Travoprost, Bimatoprost

Indication : Glaucoma
Route of Administration : Drops

## - END SCHEDULE 4 -

## SCHEDULE 5 AND SPECIFIED SCHEDULE 5

- a. All preparations or mixtures of such substances containing or purporting to contain substances that is chemically related and incorporates a structural fragment into its structure that is similar to the structure of a listed substance and /or exhibits pharmacodynamic properties similar to the listed substance referred to in this Schedule include the following:
  - (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and
  - (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.
  - (iii) all homologues of listed substances (being any chemically related substances that incorporate a structural fragment into their structures that is similar to the structure of a listed substance and/or exhibit pharmacodynamic properties similar to the listed substance in the schedules), unless listed separately in the Schedules.

- b. In terms of Section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974, other than a medical practitioner or dentist, may prescribe and apply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Medicines Control Council, to patients under his/her care, the Schedule 5 and Specified Schedule 5 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act.
  - (i) Annexure 1A: Emergency Care Provider (Paramedic);
    - Annexure 1B: Emergency Care Provider (Emergency Care Practitioner).
    - Annexure 1E: Emergency Care Technician
- c. Specified Schedule 5 substances listed in this schedule are subject to additional control in terms of section 22A of the Act as required under the provisions of the 1971 Convention on Psychotropic Substances and are denoted by \*\*

## Esketamine

#### Lemborexant

[Recombinant human epidermal growth factor (rhEGF)]

#### - END SCHEDULE 5 -

## **SCHEDULE 7**

All preparations or mixture of such substances containing or purporting to contain substances referred to in this Schedule include the following (unless expressly excluded or unless listed in another Schedule):

- the isomers of such substances, where the existence of such isomers is possible within the chemical designation;
- (ii) the esters and ethers of such substances and of the isomers referred to in(i), as well as the isomers of such esters and ethers, where the existence of isomers of such esters, or ethers is possible;
- (iii) the salts of such substances and of the isomers referred to in (i), as well as the salts of the esters, ethers and isomers referred to in (ii), where the existence of such salts is possible;

- (iv) the isomers of any of the salts referred to in (iii), where the existence of such isomers is possible;
- (v) all preparations and mixtures of any of the above.
- (vi) all homologues of listed substances (being any chemically related substances that incorporate a structural fragment into their structures that is similar to the structure of a listed substance and/or exhibit pharmacodynamic properties similar to the listed substance in the schedules), unless listed separately in the Schedules.

**Brorphine** 

<u>Eutylone</u>

<u>Metonitazene</u>

<u>Norfentanyl</u>

# - END SCHEDULE 7 -

These Schedules as amended come into operation on the date of publication in the Government *Gazette*.

DR M./ PHAAHLA, MP

MINISTER OF HEALTH

DATE: 06/10/2022